Increasing evidence demonstrates that many biological factors need to be delivered locally in order to be safe and efficacious. The indications listed below are all well suited for the EC BiodeliveryTM platform:
Huntington's disease
Parkinson's disease
Amyotrophic lateral sclerosis
Neuropathy and central pain
Multiple sclerosis
Brain and spinal cord injuries
Stroke
Neoplasm
Psychiatric disorders
Above mentioned diseases constitute a large product pipeline for the Company. The clinical rationale for treating these disease indications with EC BiodeliveryTM products is being evaluated in academic and corporate collaborations.
